Schedule of Warrants Outstanding |
|
|
September
30, |
|
|
December
31, |
|
|
|
2017 |
|
|
2016 |
|
Issued to Investors
on July 28, 2010, entitling the holders to purchase 207,000 common shares in the Company at an exercise price of $45.00 per
common share up to and including July 27, 2017. At September 30, 2017, these warrants had expired and at December 31, 2016,
the fair value of these warrants was not significant. |
|
|
- |
|
|
|
207,000 |
|
|
|
|
|
|
|
|
|
|
Issued to Investors
on October 25, 2013, entitling the holders to purchase 250,000 common shares in the Company at an exercise price of $11.50
per common share up to and including April 24, 2021. In 2016, 59,450 of these warrants were exchanged for common stock, and
all remaining warrant holders agreed to new warrant terms in exchange for a reduced exercise price of $6.25 per share. |
|
|
163,986 |
|
|
|
163,986 |
|
|
|
|
|
|
|
|
|
|
Issued to Investors
on November 17, 2014, entitling the holders to purchase 546,919 common shares in the Company at an exercise price of $11.55
per common share up to and including May 16, 2022. On June 30, 2016, the warrant holders agreed to new warrant terms in exchange
for a reduced exercise price of $6.25 per share. |
|
|
546,919 |
|
|
|
546,919 |
|
|
|
|
|
|
|
|
|
|
Issued to an Investor
on June 28, 2016, entitling the holders to purchase 295,267 common shares in the Company at an exercise price of $0.05 per
common share (pre-funded) up to and including June 27, 2021, all warrants exercised on July 12, 2017. |
|
|
- |
|
|
|
295,267 |
|
|
|
|
|
|
|
|
|
|
Issued to an investor
on August 10, 2016, entitling the holders to purchase 500,000 common shares in the Company at an exercise price of price of
$0.01 per share, up to and including December 31, 2019. |
|
|
500,000 |
|
|
|
500,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
1,210,905 |
|
|
|
1,713,172 |
|
|
Schedule of Share-based Compensation, Stock Options, Activity |
|
|
|
|
|
Weighted |
|
|
Weighted |
|
|
|
|
|
|
Average |
|
|
Average |
|
|
|
Options |
|
|
Exercise |
|
|
Grant
Date |
|
|
|
Outstanding |
|
|
Price |
|
|
Fair
Value |
|
Beginning
of the period |
|
|
2,172,581 |
|
|
$ |
6.70 |
|
|
$ |
4.83 |
|
Granted
|
|
|
31,425 |
|
|
$ |
1.08 |
|
|
$ |
0.81 |
|
Exercised
|
|
|
-- |
|
|
|
-- |
|
|
|
-- |
|
Forfeited
|
|
|
-- |
|
|
|
-- |
|
|
|
-- |
|
Expired
|
|
|
(28,671 |
) |
|
$ |
40.35 |
|
|
$ |
35.15 |
|
End
of the period |
|
|
2,175,335 |
|
|
$ |
6.17 |
|
|
$ |
4.37 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options
exercisable |
|
|
1,762,385 |
|
|
$ |
6.56 |
|
|
$ |
4.70 |
|
|
Schedule of Non-Vested Shares, Activity |
|
|
|
|
|
Weighted- |
|
|
|
|
|
|
|
|
|
Average
Fair |
|
|
Weighted |
|
|
|
|
|
|
Value |
|
|
Average |
|
|
|
Shares |
|
|
Grant
Date |
|
|
Exercise
Price |
|
Non-vested
Shares |
|
|
|
|
|
|
|
|
|
Non-vested
- December 31, 2015 |
|
|
359,001 |
|
|
$ |
4.55 |
|
|
$ |
6.70 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
1,210,467 |
|
|
$ |
1.71 |
|
|
$ |
3.02 |
|
Vested
|
|
|
(1,118,992 |
) |
|
$ |
1.81 |
|
|
$ |
3.19 |
|
Forfeited
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Non-vested
- December 31, 2016 |
|
|
450,476 |
|
|
$ |
3.60 |
|
|
$ |
5.40 |
|
Granted
|
|
|
31,425 |
|
|
|
0.81 |
|
|
|
1.08 |
|
Vested
|
|
|
(68,951 |
) |
|
$ |
5.89 |
|
|
$ |
8.82 |
|
Forfeited
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Non-vested
- September 30, 2017 |
|
|
412,950 |
|
|
$ |
3.00 |
|
|
$ |
4.51 |
|
|